Heron Therapeutics Resets Balance Sheet and Withdraws 2026 Guidance After CINVANTI Patent Ruling
核心洞察
Heron Therapeutics (搜索) reported Q2 2026 net revenue of $37.7 million, up 9% from the prior quarter but below internal expectations, with acute care revenue growing 43.9% year over year.
The company withdrew its full-year 2026 guidance following a June 2026 U.S. District Court decision affecting CINVANTI patents, citing an inability to forecast potential generic entry timing.
Heron amended its credit facility with Hercules Capital, resetting financial covenants through 2027 and reducing outstanding principal by up to $17.5 million.
Heron Therapeutics (搜索), Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, reported second quarter 2026 net revenue of $37.7 million, representing 9% growth from the first quarter of 2026 and a 1.3% increase from the prior year. The results, however, fell short of the company's internal expectations, prompting a balance sheet reset, tightened spending, and the withdrawal of full-year financial guidance.
"Second quarter revenue grew compared to the first quarter but came in below our expectations," said Craig Collard, Chief Executive Officer of Heron. "What we did over the past ninety days matters more: we reset our balance sheet, tightened our spending, and we are considering strategic alternatives as we continue to execute our current plan. Our job now is execution."
Acute Care Franchise Drives Growth
The company's Acute Care franchise delivered net revenue of $15.3 million in the second quarter, an increase of 43.9% year over year. ZYNRELEF contributed $11.1 million, reflecting 35% growth year over year and a 9% increase from the first quarter. Average daily units for ZYNRELEF grew 19% year over year, which Chief Operating Officer Mark Hensley characterized as a "site-by-site, case-by-case adoption curve."
APONVIE contributed $4.2 million in net revenue, growing 74% year over year and 26% from the first quarter. The product reached 23% share of the surgical NK-1 segment, an increase of 2 percentage points from the first quarter of 2026. Pharmacy and Therapeutics (P&T) committee approvals now stand at 1,810 accounts, representing a potential annual volume of 6.7 million medium- to high-risk procedures.
Oncology Franchise Faces Patent Headwinds
The Oncology Supportive Care franchise generated $22.3 million in net revenue for the quarter, a 15.9% decline year over year. CINVANTI contributed $21.8 million, down 9.7% year over year, which management attributed to branded competition. SUSTOL contributed $0.5 million as the company continues its planned wind-down of the product.
The franchise's outlook was significantly altered by a June 2026 decision from the U.S. District Court for the District of Delaware regarding certain patents covering CINVANTI. "When the decision from the U.S. District Court for the District of Delaware regarding certain patents covering CINVANTI changed the outlook for the company, we went to our lender," Collard stated.
CINVANTI held a 25% market share in June, consistent with its 12-month average, with 1,241 ordering accounts in line with the 12-month average of approximately 1,200 accounts. The company has filed an appeal of the court decision and is executing a defense strategy built around the clinical profile of the product, customer relationships, and contracting position.
Balance Sheet Restructuring and Guidance Withdrawal
Heron amended its credit facility with Hercules Capital, resetting financial covenants through 2027 and reducing outstanding principal by a total potential reduction of $17.5 million — $13.5 million paid at execution and a potential further $4 million reduction scheduled on or before September 15, 2026.
The company ended the quarter with $42.7 million in cash, cash equivalents, and short-term investments. Following the initial debt principal repayment, pro forma cash is approximately $28.5 million, and approximately $24.3 million after the September payment.
Heron withdrew its previously issued full-year 2026 guidance of $173 million to $183 million in net product sales and $10 million to $20 million in adjusted EBITDA. Chief Financial Officer Ira Duarte explained three factors driving the decision: the June court decision creating uncertainty around generic entry timing for CINVANTI, the company's own pause of the sales force expansion and spending tightening, and the consideration of strategic alternatives.
"This is a forecasting decision, not a statement about the underlying business," Duarte said. "We would make the same decision regardless of the quarter's results."
Financial Performance
Gross margin for the quarter was 69.3%, reflecting the current product mix and manufacturing efficiencies. Research and development expenses were $2.7 million, down from $2.9 million in the prior year quarter. Selling, general, and administrative expenses totaled $25.4 million, including the pause in planned sales force expansion.
The company reported an operating loss of $2.0 million and a net loss of $5.5 million, compared to a net loss of $2.4 million in the second quarter of 2025. Adjusted EBITDA was $3.2 million, up from $2.2 million in the comparable prior year quarter, reflecting disciplined expense management.
Strategic Review Underway
Management confirmed the company is actively considering strategic alternatives while continuing to execute its current plan. The company has not set a timetable for this process, and there can be no assurance that it will result in any transaction.
Collard described the period as a "demanding stretch" and a "hard quarter" following a patent decision the company intends to appeal, while emphasizing that the team "stayed focused on patients and customers through all of it."